Improvement in Biomarkers of Bone Formation During Infliximab Therapy in Pediatric Crohn's Disease: Results of the REACH Study

Clinical Gastroenterology and Hepatology

Volumn 6, Issue 12, 2008, Pages 1378-1384

  Thayu, Meena ^a   Leonard, Mary B ^a   Hyams, Jeffrey S ^b   Crandall, Wallace V ^c   Kugathasan, Subra ^d   Otley, Anthony R ^e   Olson, Allan ^j   Johanns, Jewel ^f   Marano, Colleen W ^f   Heuschkel, Robert B ^g   Veereman Wauters, Gigi ^h   Griffiths, Anne M ⁱ   Baldassano, Robert N ^a  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b Farmington   (United States)

^c NATIONWIDE CHILDREN S HOSPITAL   (United States)

^d MEDICAL COLLEGE OF WISCONSIN   (United States)

^e IWK HEALTH CENTRE   (Canada)

^f CENTOCOR INC   (United States)

^g ROYAL FREE HOSPITAL   (United Kingdom)

^h Queen Paola Children's Hospital   (Belgium)

ⁱ HOSPITAL FOR SICK CHILDREN   (Canada)

^j RW Johnson Pharmaceutical Research and Development   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; BIOLOGICAL MARKER; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN TYPE 1; DEOXYPYRIDINOLINE; INFLIXIMAB; MESALAZINE; METHOTREXATE; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; AGE; ARTICLE; BONE METABOLISM; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORRELATION ANALYSIS; CROHN DISEASE; DRUG DOSE REDUCTION; DRUG EFFICACY; FEMALE; GENDER; HEIGHT; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OSSIFICATION; OSTEOBLAST; OSTEOLYSIS; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD;

ADOLESCENT; ALKALINE PHOSPHATASE; ANTIBODIES, MONOCLONAL; CHILD; COLLAGEN TYPE I; CROHN DISEASE; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; MALE; OSTEOGENESIS; PEPTIDES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 57149094224     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2008.07.010     Document Type: Article

References (42)

1. Mamula P., Markowitz J., and Baldassano R.N. Inflammatory bowel disease in early childhood and adolescence: special considerations. Gastroenterol Clin North Am 32 (2003) 967-995
2. Burnham J.M., Shults J., Semeao E., et al. Whole body BMC in pediatric Crohn disease: independent effects of altered growth, maturation, and body composition. J Bone Miner Res 19 (2004) 1961-1968
3. Hyams J.S., Wyzga N., Kreutzer D.L., et al. Alterations in bone metabolism in children with inflammatory bowel disease: an in vitro study. J Pediatr Gastroenterol Nutr 24 (1997) 289-295
4. Burnham J.M., Shults J., Semeao E., et al. Alteration is proximal femur geometry in children treated with glucocorticoids for Crohn diease or nephrotic syndrome: impact of the underlying disease. J Bone Miner Res 22 (2007) 551-559
5. Pollak R.D., Karmeli F., Eliakim R., et al. Femoral neck osteopenia in patients with inflammatory bowel disease. Am J Gastroenterol 93 (1998) 1483-1490
6. Bischoff S.C., Herrmann A., Goke M., et al. Altered bone metabolism in inflammatory bowel disease. Am J Gastroenterol 92 (1997) 1157-1163
7. Thearle M., Horlick M., Bilezikian J.P., et al. Osteoporosis: an unusual presentation of childhood Crohn's disease. J Clin Endocrinol Metab 85 (2000) 2122-2126
8. Semeao E.J., Jawad A.F., Zemel B.S., et al. Bone mineral density in children and young adults with Crohn's disease. Inflamm Bowel Dis 5 (1999) 161-166
9. Semeao E.J., Stallings V.A., Peck S.N., et al. Vertebral compression fractures in pediatric patients with Crohn's disease. Gastroenterology 112 (1997) 1710-1713
10. van Staa T.P., Cooper C., Brusse L.S., et al. Inflammatory bowel disease and the risk of fracture. Gastroenterology 125 (2003) 1591-1597
11. Bernstein C.N., Blanchard J.F., Leslie W., et al. The incidence of fracture among patients with inflammatory bowel disease: a population-based cohort study. Ann Intern Med 133 (2000) 795-799
12. Loftus Jr. E.V., Crowson C.S., Sandborn W.J., et al. Long-term fracture risk in patients with Crohn's disease: a population-based study in Olmsted County, Minnesota. Gastroenterology 123 (2002) 468-475
13. Khosla S., and Kleerekoper M. Biochemical markers of bone turnover. In: Favus M.J. (Ed). Primer on the metabolic bone diseases and disorders of mineral metabolism (2003), American Society for Bone and Mineral Research, Washington, DC 166-172
14. Schoon E.J., Geerling B.G., Van Dooren I.M., et al. Abnormal bone turnover in long-standing Crohn's disease in remission. Aliment Pharmacol Ther 15 (2001) 783-792
15. Robinson R.J., Iqbal S.J., Abrams K., et al. Increased bone resorption in patients with Crohn's disease. Aliment Pharmacol Ther 12 (1998) 699-705
16. Schonau E., and Rauch F. Biochemical markers of bone metabolism. In: Glorieux F.H. (Ed). Pediatric bone: biology and diseases (2003), Academic Press, San Diego 339-357
17. Szulc P., Seeman E., and Delmas P.D. Biochemical measurements of bone turnover in children and adolescents. Osteoporos Int 11 (2000) 281-294
18. Sylvester F.A., Wyzga N., Hyams J.S., et al. Natural history of bone metabolism and bone mineral density in children with inflammatory bowel disease. Inflamm Bowel Dis 13 (2007) 42-50
19. Tuchman S., Thayu M., Zemel B.S., et al. Interpretation of biomarkers of bone metabolism in children: impact of growth velocity and body size in healthy children and chronic disease. J Pediatr 153 (2008) 484-490
20. Gilbert L., He X., Farmer P., et al. Inhibition of osteoblast differentiation by tumor necrosis factor-alpha. Endocrinology 141 (2000) 3956-3964
21. Guttridge D.C., Mayo M.W., Madrid L.V., et al. NF-kappaB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. Science 289 (2000) 2363-2366
22. Kwan Tat S., Padrines M., Theoleyre S., et al. IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology. Cytokine Growth Factor Rev 15 (2004) 49-60
23. Ryan B.M., Russel M.G., Schurgers L., et al. Effect of antitumour necrosis factor-alpha therapy on bone turnover in patients with active Crohn's disease: a prospective study. Aliment Pharmacol Ther 20 (2004) 851-857
24. Miheller P., Muzes G., Racz K., et al. Changes of OPG and RANKL concentrations in Crohn's disease after infliximab therapy. Inflamm Bowel Dis 13 (2007) 1379-1384
25. Franchimont N., Putzeys V., Collette J., et al. Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease. Aliment Pharmacol Ther 20 (2004) 607-614
26. Abreu M.T., Geller J.L., Vasiliauskas E.A., et al. Treatment with infliximab is associated with increased markers of bone formation in patients with Crohn's disease. J Clin Gastroenterol 40 (2006) 55-63
27. Hyams J., Crandall W., Kugathasan S., et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology 132 (2007) 863-873 quiz 1165-1166
28. Ogden C.L., Kuczmarski R.J., Flegal K.M., et al. Centers for Disease Control and Prevention 2000 growth charts for the United States: improvements to the 1977 National Center for Health Statistics version. Pediatrics 109 (2002) 45-60
29. Greulich W.W., and Pyle S.I. Radiographic atlas of skeletal development of the hand and wrist (1959), Stanford University Press, Palo Alto, CA
30. Rauchenzauner M., Schmid A., Heinz-Erian P., et al. Sex- and age-specific reference curves for serum markers of bone turnover in healthy children from 2 months to 18 years. J Clin Endocrinol Metab 92 (2007) 443-449
31. Blumsohn A., Hannon R.A., Wrate R., et al. Biochemical markers of bone turnover in girls during puberty. Clin Endocrinol (Oxf) 40 (1994) 663-670
32. Gilbert L., He X., Farmer P., et al. Expression of the osteoblast differentiation factor RUNX2 (Cbfa1/AML3/Pebp2alpha A) is inhibited by tumor necrosis factor-alpha. J Biol Chem 277 (2002) 2695-2701
33. Radeff J.M., Nagy Z., and Stern P.H. Involvement of PKC-beta in PTH, TNF-alpha, and IL-1 beta effects on IL-6 promoter in osteoblastic cells and on PTH-stimulated bone resorption. Exp Cell Res 268 (2001) 179-188
34. Lee S.E., Chung W.J., Kwak H.B., et al. Tumor necrosis factor-alpha supports the survival of osteoclasts through the activation of Akt and ERK. J Biol Chem 276 (2001) 49343-49349
35. Pereira R.C., Delany A.M., and Canalis E. Effects of cortisol and bone morphogenetic protein-2 on stromal cell differentiation: correlation with CCAAT-enhancer binding protein expression. Bone 30 (2002) 685-691
36. Canalis E., Bilezikian J.P., Angeli A., et al. Perspectives on glucocorticoid-induced osteoporosis. Bone 34 (2004) 593-598
37. Hofbauer L.C., Gori F., Riggs B.L., et al. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology 140 (1999) 4382-4389
38. Hanauer S.B., Feagan B.G., Lichtenstein G.R., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359 (2002) 1541-1549
39. Rutgeerts P., Feagan B., Lichtenstein G., et al. Comparison of Scheduled and Episodic Treatment Strategies of Infliximab in Crohn's Disease. Gastoenterology 126 (2004) 402-413
40. van Coeverden S.C., Netelenbos J.C., de Ridder C.M., et al. Bone metabolism markers and bone mass in healthy pubertal boys and girls. Clin Endocrinol (Oxf) 57 (2002) 107-116
41. Sylvester F.A., Davis P.M., Wyzga N., et al. Are activated T cells regulators of bone metabolism in children with Crohn disease?. J Pediatr 148 (2006) 461-466
42. Bernstein M., Irwin S., and Greenberg G.R. Maintenance infliximab treatment is associated with improved bone mineral density in Crohn's disease. Am J Gastroenterol 100 (2005) 2031-2035